Middle East Tech Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East Tech Today.

Press releases published on July 8, 2026

OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain
Aurora Mobile's EngageLab Showcases AI-First Omnichannel Customer Engagement Solutions at The MarTech Summit Hong Kong
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
Quest Software Strengthens Identity Security and Resilience for the AI Era, Achieving FedRAMP® High Authorized Certification for Identity Defense and Identity Recovery
 Virtune lists the Virtune Hyperliquid ETP on Nasdaq Stockholm and Nasdaq Helsinki
Virtune noterar Virtune Hyperliquid ETP på Nasdaq Stockholm och Nasdaq Helsinki
Virtune listaa Virtune Hyperliquid ETP:n Nasdaq Tukholmaan ja Nasdaq Helsinkiin
UK businesses drastically overestimate their AI progress
ESET Threat Report: AI boosts cyber attackers’ efficiency
Herstel is de benchmark van veerkracht
AMSilk and Ajinomoto Foods Europe Expand Partnership to Enable Industrial-Scale Production of Silk Proteins
The Board Decision Gap: AI Transforms the Deal, But Boards Still Govern the Outcome
On World Obesity Day, WONDERLAB Releases the Targeted Microbiota Weight Management White Paper
New Prop Firm DojoTraders Launches and Aims to Simplify Trading Across Markets
Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
June 2026 Quarter Production Update
Snail Games 推出《方舟:创世崛起》第一部分、《方舟:命运之潮》及《方舟:龙之乌托邦》DLC;1,100 万美元递延收入积压将于 2026 年第三季度确认
Snail Games 推出《方舟:創世崛起》第一部分、《方舟:財富之潮》及《方舟:龍之烏托邦》可下載內容;遞延收入積壓中的 1,100 萬美元將於 2026 年第三季度確認
Vivani Medical schließt Vereinbarung mit Novo Nordisk zur Evaluierung von NPM-139, einem miniaturisierten, ultra-langwirkenden Semaglutid-Implantat zur langfristigen Gewichtsregulierung
Vivani Medical conclut un accord avec Novo Nordisk pour évaluer le NPM-139, un implant miniature à base de sémaglutide à action ultra-prolongée destiné au traitement de l’obésité

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Middle East Tech Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.